These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33684684)

  • 21. Anticancer activity of 8-hydroxyquinoline-triphenylphosphine rhodium(III) complexes targeting mitophagy pathways.
    Huang XQ; Wu RC; Liang JM; Zhou Z; Qin QP; Liang H
    Eur J Med Chem; 2024 Jun; 272():116478. PubMed ID: 38718624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similarities and differences in d
    Gilewska A; Barszcz B; Masternak J; Kazimierczuk K; Sitkowski J; Wietrzyk J; Turlej E
    J Biol Inorg Chem; 2019 Jun; 24(4):591-606. PubMed ID: 31115765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted liposomes encapsulated iridium(III) compound greatly enhance anticancer efficacy and induce cell death via ferroptosis on HepG2 cells.
    Chen J; Li W; Li G; Liu X; Huang C; Nie H; Liang L; Wang Y; Liu Y
    Eur J Med Chem; 2024 Feb; 265():116078. PubMed ID: 38141286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysosome-targeted cyclometalated iridium(III) complexes: JMJD inhibition, dual induction of apoptosis, and autophagy.
    Lu JJ; Ma XR; Xie K; Chen MR; Huang B; Li RT; Ye RR
    Metallomics; 2022 Sep; 14(9):. PubMed ID: 36073756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, Characterization and Anticancer Efficacy Studies of Iridium (III) Polypyridyl Complexes against Colon Cancer HCT116 Cells.
    Xie B; Wang Y; Wang D; Xue X; Nie Y
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption.
    Wan D; Tang B; Wang YJ; Guo BH; Yin H; Yi QY; Liu YJ
    Eur J Med Chem; 2017 Oct; 139():180-190. PubMed ID: 28800456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Search for new biologically active compounds:
    Mitrović M; Djukić MB; Vukić M; Nikolić I; Radovanović MD; Luković J; Filipović IP; Matić S; Marković T; Klisurić OR; Popović S; Matović ZD; Ristić MS
    Dalton Trans; 2024 Jun; 53(22):9330-9349. PubMed ID: 38747564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of substituents on DNA and protein binding of cyclometalated Ir(iii) complexes and anticancer activity.
    Mukhopadhyay S; Singh RS; Paitandi RP; Sharma G; Koch B; Pandey DS
    Dalton Trans; 2017 Jul; 46(26):8572-8585. PubMed ID: 28640302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and characterization of polypyridine ruthenium(II) complexes and anticancer efficacy studies in vivo and in vitro.
    Liang L; Wu X; Shi C; Wen H; Wu S; Chen J; Huang C; Wang Y; Liu Y
    J Inorg Biochem; 2022 Nov; 236():111963. PubMed ID: 35988387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potent anticancer copper(ii) complexes containing tripodal bis[2-ethyl-di(3,5-dialkyl-1H-pyrazol-1-yl)]amine moiety.
    Massoud SS; Louka FR; Dial MT; Malek AJ; Fischer RC; Mautner FA; Vančo J; Malina T; Dvořák Z; Trávníček Z
    Dalton Trans; 2021 Sep; 50(33):11521-11534. PubMed ID: 34346447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclometalated iridium(III) complexes as mitochondria-targeted anticancer and antibacterial agents to induce both autophagy and apoptosis.
    Chen BB; Pan NL; Liao JX; Huang MY; Jiang DC; Wang JJ; Qiu HJ; Chen JX; Li L; Sun J
    J Inorg Biochem; 2021 Jun; 219():111450. PubMed ID: 33826973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclometalated iridium(III) dithioformic acid complexes as mitochondria-targeted imaging and anticancer agents.
    Wu Y; Liu J; Shao M; Zhang P; Song S; Yang G; Liu X; Liu Z
    J Inorg Biochem; 2022 Aug; 233():111855. PubMed ID: 35576884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, structural characterization and antitumor activity of six rare earth metal complexes with 8-hydroxyquinoline derivatives.
    Yang QY; Cao QQ; Zhang YL; Xu XF; Deng CX; Kumar R; Zhu XM; Wang XJ; Liang H; Chen ZF
    J Inorg Biochem; 2020 Oct; 211():111175. PubMed ID: 32858466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rhodium(III)-Picolinamide Complexes Act as Anticancer and Antimetastasis Agents via Inducing Apoptosis and Autophagy.
    Gu YQ; Yang K; Yang QY; Li HQ; Hu MQ; Ma MX; Chen NF; Liu YH; Liang H; Chen ZF
    J Med Chem; 2023 Jul; 66(14):9592-9606. PubMed ID: 37432720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rhodium(III) and iridium(III) complexes with 1,2-naphthoquinone-1-oximate as a bidentate ligand: synthesis, structure, and biological activity.
    Wirth S; Rohbogner CJ; Cieslak M; Kazmierczak-Baranska J; Donevski S; Nawrot B; Lorenz IP
    J Biol Inorg Chem; 2010 Mar; 15(3):429-40. PubMed ID: 20091072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer mechanism studies of iridium(III) complexes inhibiting osteosarcoma HOS cells proliferation.
    Xie FL; Wang Y; Zhu JW; Xu HH; Guo QF; Wu Y; Liu SH
    J Inorg Biochem; 2022 Dec; 237():112011. PubMed ID: 36252336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced in vitro cytotoxicity and antitumor activity in vivo of iridium(III) complexes liposomes targeting endoplasmic reticulum and mitochondria.
    Li W; Wu X; Liu H; Shi C; Yuan Y; Bai L; Liao X; Zhang Y; Liu Y
    J Inorg Biochem; 2022 Aug; 233():111868. PubMed ID: 35636300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of Camphor-Derived Bis(pyrazolylpyridine) Rhodium(III) Complexes: Structure-Reactivity Relationships and Biological Activity.
    Petrović A; Milutinović MM; Petri ET; Živanović M; Milivojević N; Puchta R; Scheurer A; Korzekwa J; Klisurić OR; Bogojeski J
    Inorg Chem; 2019 Jan; 58(1):307-319. PubMed ID: 30565467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomes encapsulated iridium(III) polypyridyl complexes enhance anticancer activity in vitro and in vivo.
    Bai L; Fei WD; Gu YY; He M; Du F; Zhang WY; Yang LL; Liu YJ
    J Inorg Biochem; 2020 Apr; 205():111014. PubMed ID: 32044395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
    Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
    Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.